유방암 아형에 따른 FDG 섭취 정도 차이 분석

Abstract

The aim of this study was to determine whether a correlation exists between SUVmax on FDG-PET and the subtypes of breast cancer. This retrospective study involved 548 patients (mean age: 51.6 years; range: 21–81 years) with 552 index breast cancers (mean size: 2.57cm; range: 1.0–14.5 cm). The correlation between 18F-FDG uptake in PET/CT, expressed as maximum standardized uptake value (SUVmax), and immunohistochemically-defined subtypes (luminal A, luminal B, human epidermal growth factor receptor 2 (HER2)-positive, and triple-negative) was analyzed. The mean SUVmax value of the 552 tumors was 6.07 ± 4.63 (range: 0.9–32.8). The subtypes of the 552 tumors were 334 (60%) luminal A; 66 (12%) luminal B; 60 (11%) HER2-positive; and 92 (17%) triple-negative; for which the mean SUVmax values were 4.69 ± 3.45; 6.51 ±4.18; 7.44 ± 4.73; and 9.83 ± 6.03, respectively. In a multivariate regression analysis, triple-negative and HER2-positive tumors had 1.67-fold (P< 0.001) and 1.27-fold (P = 0.009) higher SUVmax values, respectively, than luminal A tumors after adjustment for invasive tumor size, lymph node involvement status, and histologic grade. FDG uptake was independently associated with subtypes of invasive breast cancer. Triple-negative and HER2-positive breast cancers showed higher SUVmax values than did luminal A tumors.